

Hae-Jin Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6682374/publications.pdf>

Version: 2024-02-01

23
papers

610
citations

686830

13
h-index

642321

23
g-index

24
all docs

24
docs citations

24
times ranked

938
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. <i>Biochemical and Biophysical Research Communications</i> , 2022, 588, 154-160. | 1.0 | 12 |
| 2 | Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Study. <i>Diabetes Care</i> , 2022, 45, 1141-1150. | 4.3 | 3 |
| 3 | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 689-700. | 1.8 | 2 |
| 4 | Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice. <i>Journal of Hepatology</i> , 2022, 77, 735-747. | 1.8 | 8 |
| 5 | Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway. <i>Biomedicines</i> , 2022, 10, 1032. | 1.4 | 6 |
| 6 | Visfatin exacerbates hepatic inflammation and fibrosis in a methionineâ€cholineâ€deficient diet mouse model. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2592-2600. | 1.4 | 14 |
| 7 | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-Î², MKK7/JNK, and JAK2/STAT1 Signalling Pathways. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11. | 0.9 | 69 |
| 8 | Acute Glucose Shift Induces the Activation of the NLRP3 Inflammasome in THP-1 Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9952. | 1.8 | 4 |
| 9 | Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. <i>Clinical Therapeutics</i> , 2020, 42, 2021-2035.e3. | 1.1 | 6 |
| 10 | CCL20 induced by visfatin in macrophages via the NF-Î² and MKK3/6-p38 signaling pathways contributes to hepatic stellate cell activation. <i>Molecular Biology Reports</i> , 2020, 47, 4285-4293. | 1.0 | 10 |
| 11 | Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 95. | 2.7 | 16 |
| 12 | Visfatin Induces Inflammation and Insulin Resistance via the NF-Î² and STAT3 Signaling Pathways in Hepatocytes. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-11. | 1.0 | 89 |
| 13 | 2018 Guidelines for the Management of Dyslipidemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 78. | 1.1 | 100 |
| 14 | The Association of Adiponectin and Visceral Fat with Insulin Resistance and Î²-Cell Dysfunction. <i>Journal of Korean Medical Science</i> , 2019, 34, e7. | 1.1 | 38 |
| 15 | Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 28. | 1.0 | 23 |
| 16 | Sodiumâ€glucose coâ€transporterâ€2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: <scp>A</scp> nationwide populationâ€based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1852-1858. | 2.2 | 46 |
| 17 | Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-10. | 1.0 | 10 |
| 18 | Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. <i>Cardiovascular Diabetology</i> , 2018, 17, 91. | 2.7 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Effect of sarpogrelate, a selective 5-HT 2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2017, 257, 47-54. | 0.4 | 13 |
| 20 | Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2017, 10, . | 1.6 | 36 |
| 21 | MicroRNA-132 Negatively Regulates Palmitate-Induced NLRP3 Inflammasome Activation through FOXO3 Down-Regulation in THP-1 Cells. <i>Nutrients</i> , 2017, 9, 1370. | 1.7 | 17 |
| 22 | Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9. | 1.0 | 33 |
| 23 | Impact of Cadmium Exposure on the Association between Lipopolysaccharide and Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 11396-11409. | 1.2 | 14 |